GlassScriptPhysician profile
Alexander Rudoi
NPI 1740254374
$8,486.90
in general payments reported to CMS, 2019-2025
48 companies · $705 in 2025
The $705 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,156 · 2020: $251 · 2021: $1,434 · 2022: $1,406 · 2023: $1,645 · 2024: $1,891 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,116 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,115.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,261.58 | 2020-2024 | Aristada, Lybalvi, Aristada Initio |
| Astrazeneca Pharmaceuticals LP | $749.46 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $690.41 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $630.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $469.86 | 2021-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $453.02 | 2019-2025 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $380.75 | 2021-2024 | Austedo Xr |
| Allergan, INC. | $279.88 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $253.20 | 2024-2025 | Fanapt |
| Harmony Biosciences LLC | $241.49 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.90 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $140.96 | 2023 | Ingrezza |
| Sumitomo Pharma America, INC. | $139.61 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.29 | 2019-2025 | Jardiance, Tradjenta |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Rudoi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.